Science and Technology Perspective

 
 

  • Technology for Primary Care — Terrific, Terrifying, or Both? The paper appointment book has been replaced by scheduling systems sometimes lacking in flexibility for double booking, sibling visits, and variable length.
  • Metastatic Breast Cancer Treatment: What the Future Holds Dr Eric Winer discusses the current state of metastatic breast cancer therapies and what the future holds, as clinicians strive to optimize patient care.
  • Lifesaving Surgery for Lungless Man   Surgical creativity and a dash of DIY helped Chicago-area man beat a devastating pulmonary infection that destroyed both of his lungs.
  • This Is Your Brain on Zoom Neurologist Leah Croll reviews a novel brain imaging study showing that virtual interactions don't access the brain's social neural pathways as effectively as live interactions.
  • Is It Possible to Predict the Risk for Pancreatic Cancer? A US-based team seeks to develop and validate a model allowing clinicians to predict the risk for pancreatic cancer.
  • AI in Oncology: Sorting Through Misinformation   David J. Kerr, CBE, MD, DSc, discusses the use of artificial intelligence in oncology now and in the future.
  • Physician-Owned Hospitals: The Answer for Better Care?   Drs Robert Glatter and Brian Miller discuss the current and renewed interest in physician-owned hospitals.
  • Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
  • The 10 Best GI Studies From 2023 That You Need to Know Dr David Johnson highlights the articles from this year that are most likely to have immediate game-changing implications in your practice.
  • Premature Babies Deserve Mature AI Clinicians in intensive care facilities don't have the privilege of being able to accept imperfect AI.
  • Beware of Biased AI   AI to "aid" physician diagnosis may not be as helpful as we expect it to be.
  • The Top Cardiology Trials of 2023   For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.
  • ASH 2023: Key Insights on Advances in DLBCL   Dr Suchitra Sundaram highlights some of the practice-changing data presented at ASH 2023.
  • Cysteamine and Melasma Cysteamine is a natural agent that has recently garnered attention primarily for one indication: melasma.
  • Quitting Medical School Why would a physician who was burdened with student loans enter a subspecialty that would limit his or her ability to pay it off?
  • Supercharge Your Medical Practice With ChatGPT An expert on artificial intelligence in oncology describes why, and how, to integrate ChatGPT into your clinical practice.
  • Advancing Cardiovascular Health Equity Through Prevention Science This review highlights achieving optimal cardiovascular health via a coordinated multidisciplinary approach. Conscious efforts to improve community engagement and health care policy are needed to mitigate inequities and achieve social justice.
  • How to Prescribe Zepbound Recently approved tirzepatide joins semaglutide as an option for patients with obesity. Beverly Tchang, MD, offers her recommendations based on her experience for prescribing.
  • The Truth About Vaping   The idea that vaping is harmless is going up in smoke. What would you tell your own kids or grandkids about e-cigarette use?
  • Is Lifelong LDL-C Lowering Within Reach?   Michelle O'Donoghue interviews Verve CEO and cardiologist Sekar Kathiresan about PCSK9 gene editing to lower LDL cholesterol and the findings of the heart-1 study.
  • HDL-C Levels' Role in Cardioprotection: 5 Things to Know Targeting HDL-C function can be an effective strategy to understand mechanisms related to CV protection, which in turn can lead to the development of newer therapies to prevent CVD.
  • Antiobesity Drugs in OA: Slow, Moderate Approach Deemed Best Rapid weight loss with antiobesity drugs had no significant impact on reduced mortality in a population-based study of more than 6000 adults with knee or hip osteoarthritis.